iTeos Therapeutics Announces New  Scientific Advisory Board Members
A2A Inhibitor Clinical Trials Corporate Research TIGIT

iTeos Therapeutics Announces New Scientific Advisory Board Members

Gosselies, Belgium and Cambridge, MA – September 9th, 2019 – iTeos Therapeutics SA (iTeos), a privately-held biotechnology company developing novel cancer immunotherapies, today announced that it has added four new world-leading experts in oncology, immunology, and drug discovery and development to its Scientific Advisory Board (SAB): Gordon Freeman,  William Hahn, Ben Stanger and Matt Vander Heiden. The SAB will support the development of iTeos’ pipeline of clinical and preclinical assets targeting key mechanisms of immunosuppression, in order to transform the lives of people living with cancer.

The full SAB comprises:

  • Gordon Freeman, Ph.D, Researcher at Boston’s Dana-Farber Cancer Institute, who will become Chairman of the SAB
  • William C. Hahn, M.D.,Ph.D, Chief Research Strategy Officer at Boston’s Dana-Farber Cancer Institute
  • Ben Z. Stanger, M.D, Professor in Cancer Research at the University of Pennsylvania’s Perelman School of Medicine
  • Matthew G. Vander Heiden, Ph.D., Associate Director at the Massachusetts Institute of Technology’s (MIT) Koch Institute for   Integrative Cancer Research
  • Benoit Van den Eynde M.D., Ph.D, Director of the Brussels Branch of the Ludwig Institute for Cancer Research, Ltd. and co-founder of iTeos and previously Chairman of the SAB, will remain a key member of the SAB
  • Pierre Coulie, M.D., Ph.D. Professor of Immunology, the De Duve Institute of the Université Catholique de Louvain
  • Scott Chappel, Ph.D. Chief Scientific Officer at iTeos Therapeutics

Michel Detheux, Ph.D., Chief Executive Officer of iTeos, commented: “By assembling this new Scientific Advisory Board, iTeos gains access to a broad range of expertise and extensive knowledge. As we advance our highly-differentiated pipeline of immunotherapies that target the tumor microenvironment, with the aim of enhancing the anti-tumor immune response and addressing some of the limitations of first-generation immunotherapies, their scientific rigour will be invaluable.

“While welcoming the new members of the SAB, I would also like to thank the retiring members including Dr. Jean-Yves Bonnefoy, Prof. Vincenzo Bronte, Prof. Vincenzo Cerundolo, Prof. Douglas Fearon, Dr. Jedd Wolchok and Dr. Thomas Gajewski. Their expertise and guidance have been integral to the growth of iTeos Therapeutics and I wish them all well in their future endeavours.”

Gordon Freeman, Chairman of the Scientific Advisory Board of iTeos, commented: “I am delighted to be working with, and chairing, the Scientific Advisory Board at iTeos Therapeutics, an exciting company that I have been aware of for a long time and have followed their progress. iTeos’ pipeline of highly selective and potent drug candidates is one that includes some of the most promising drug candidates targeting the A2A pathway as well as TIGIT, a second-generation immune checkpoint inhibitor that is gaining increased interest from big pharma and will enter the clinic in the second half of 2019. I look forward to advising the team through the next stages of their clinical development.”

Additional background on all SAB members can be found on the iTeos website.

For further information, please contact:

Michel Detheux, CEO

iTeos Therapeutics

info@iteostherapeutics.com

 

Amber Fennell, Mathew Neal, Sukaina Virji, and Catherine London (US)

Consilium Strategic Communications

+44 203 709 5700

iteos@consilium-comms.com

 

Sarah McCabe and Carl Mauch

Stern Investor Relations, Inc.

+ 1 212 362 1200

iTeos@sternir.com

Related news

  • iTeos Therapeutics Presents Data from First-in-Human Study of A2A Receptor Antagonist at AACR Virtual Annual Meeting 2020
    A2A Inhibitor Corporate

    iTeos Therapeutics Presents Data from First-in-Human Study of A2A Receptor Antagonist at AACR Virtual Annual Meeting 2020

    – Initial data from the dose escalation portion of the Phase 1/2a trial in 21 cancer patients with advanced solid tumors shows EOS-850 was well tolerated with no dose-limiting toxicities observed – – EOS-850 showed preliminary single-agent clinical benefit in seven patients who continue to present with at least stable disease; two partial responses in heavily-pretreated patients are ongoing – – Identification of recommended Phase 2 dose showing strong foundation for planned expansion cohorts to evaluate EOS-850 as a monotherapy and in combination for several solid tumor indications – Gosselies, Belgium and Cambridge, MA – April 27, 2020. iTeos Therapeutics, a privately-held clinical-stage biotechnology company developing novel cancer immunotherapies, announced today that it will present initial data from the Phase 1 portion of the study of its selective and differentiated A2A receptor antagonist, EOS-850, in a poster presentation at the American Association of Cancer Research (AACR) Virtual Annual Meeting 2020. “We are excited by these data from the Phase 1 portion of the study, in which our highly selective A2A antagonist, EOS-850, had a favorable tolerability profile, as well as promising clinical responses, in cancer patients with advanced solid tumors,” said Joanne Jenkins Lager, M.D., Chief Medical Officer of iTeos Therapeutics. “We have established a recommended Phase 2 dose that was well tolerated and demonstrated favorable target coverage. The single-agent activity, demonstrated by two partial responses in heavily pre-treated patients, shows that EOS-850 is an active drug with a good therapeutic index. These data set a strong foundation for moving into the next stage of development in several expansion cohorts, whether as a single agent or in combination with Merck’s KEYTRUDA® or chemotherapy standard of care agents.” The Phase 1 dose escalation portion of the EOS-850 trial enrolled 21 advanced cancer patients with solid tumors. The trial was a 3 + 3 design and patients were enrolled in five dose levels, receiving EOS-850 orally either once a day (QD) or twice a day (BID). Additional patients could be enrolled at previously cleared dose levels to better define safety, pharmacokinetics and pharmacodynamics. The dose levels tested were 20 mg and 40 mg QD, and 40 mg, 80 mg and 160 mg BID. The primary objectives of the Phase 1 portion of the study were to evaluate the safety and tolerability of EOS-850 and to determine a recommended Phase 2 dose. Secondary study objectives include pharmacokinetic and pharmacodynamic assessment of EOS-850 monotherapy and monotherapy efficacy activity of EOS-850. Summary of the Data Presented All QD and BID dose levels were well-tolerated with no grade 3 or 4 drug-related adverse events. No dose limiting toxicities were observed. Assessment of the pharmacodynamic effects of EOS-850 in assays assessing phosphorylation of CREB and cytokine production, performed by taking blood samples from patients at various time points following administration, demonstrated sustained inhibition of the A2A receptor. Pharmacokinetic analysis demonstrated good dose-proportionality through 80mg BID, the recommended Phase 2 dose. EOS-850 demonstrated preliminary evidence of single-agent activity in seven patients, each of whom had at least stable disease. Ongoing partial responses were seen in a patient with heavily pre-treated checkpoint inhibitor-refractory melanoma and in a patient with metastatic hormone- and chemotherapy-resistant prostate cancer. The abstract and video presentation details are as follows:  Title: First in human study with EOS100850, a novel potent A2A antagonist, shows excellent tolerance and clinical benefit in immune resistant advanced cancers (CT152)  Session: Phase I Clinical Trials  Abstract #: 10228  Authors: Laurence Buisseret, et al. The video presentation and full abstract will be available on the AACR conference website as of 9:00 AM ET on Monday, April 27th. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., USA. EOS-850 Further Clinical Development Plans The primary and secondary endpoints of the dose escalation portion of the Phase 1/2a trial have been met at the recommended Phase 2 dose of 80mg BID. Based on these results, as well as the partial responses observed in two cancer patients with advanced disease, the Company is moving into the expansion cohorts of the study. These cohorts will test EOS-850 as a single agent and in combination with KEYTRUDA® (pembrolizumab) and in combination with chemotherapy. Indications for testing include checkpoint-resistant melanoma, metastatic hormone-resistant prostate cancer, triple-negative breast cancer, endometrial cancer and non-small cell lung cancer. The combination studies will include a safety evaluation of the combinations and then enroll patients in two-stage tumor-specific expansions. Preliminary results of these expansions are expected in the first half of 2021. About iTeos Therapeutics iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to transforming the lives of people living with cancer by designing and developing next generation immunotherapies targeting two key resistance pathways to checkpoint therapy: the adenosine pathway and regulatory T cells (Tregs). The Company’s lead program, EOS-850, is a potentially best-in-class adenosine A2A receptor antagonist currently in a Phase 1/2a trial. Its second program, a fully human ADCC-enabling anti-TIGIT antibody (EOS-448), entered the clinic in February 2020. The Company recently closed a $125 million Series B-2 financing from leading biotech investors including RA Capital, Boxer Capital, MPM Capital, Janus Henderson Advisors, RTW Investments, Invus, HBM Partners, Fund+, Vives II, SRIW and SFPI . iTeos Therapeutics is headquartered in Cambridge, MA with a research center in Gosselies, Belgium. For more information, please visit www.iteostherapeutics.com.   For further information, please contact: Michel Detheux, CEO iTeos Therapeutics SA info@iteostherapeutics.com   Amber Fennell, Paul Kidwell, Matthew Neal and Sukaina Virji Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com   Sarah McCabe and Zofia Mita Stern Investor Relations, Inc. + 1 212 362 1200 iTeos@sternir.com  

  • iTeos Therapeutics to Present Data from First- in-Human Study of A2A Receptor Antagonist at AACR Virtual Annual Meeting 2020
    A2A Inhibitor Corporate Research

    iTeos Therapeutics to Present Data from First- in-Human Study of A2A Receptor Antagonist at AACR Virtual Annual Meeting 2020

    Gosselies, Belgium and Cambridge, MA – April 20, 2020. iTeos Therapeutics, a privately-held biotechnology company developing novel cancer immunotherapies, announces today that it will present initial data on the first-in-human study of its highly innovative and differentiated A2A receptor antagonist, EOS-850 in a virtual poster presentation at the upcoming American Association of Cancer Research (AACR) Virtual Annual Meeting 2020, taking place April 27-28th.     The abstract and video presentation details are as follows: Title: First in human study with EOS100850, a novel potent A2A antagonist, shows excellent tolerance and clinical benefit in immune resistant advanced cancers (CT152) Session: Phase I Clinical Trials Abstract #: 10228 Authors: Laurence Buisseret, et al. The video presentation and full abstract will be available on the AACR conference website from 9:00 AM ET on Monday, April 27th. For further information, please contact: Michel Detheux, CEO iTeos Therapeutics SA info@iteostherapeutics.com Amber Fennell, Paul Kidwell, Matthew Neal and Sukaina Virji Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com Sarah McCabe and Zofia Mita Stern Investor Relations, Inc. + 1 212 362 1200 iTeos@sternir.com

  • iTeos Therapeutics Closes $125 Million Series B2 Financing
    A2A Inhibitor Clinical Trials Corporate Financial Research TIGIT

    iTeos Therapeutics Closes $125 Million Series B2 Financing

     - Proceeds support advancing clinical development of next-generation cancer immunotherapies targeting A2A adenosine receptor and anti-TIGIT immune checkpoint - - Oversubscribed round co-led by new investors RA Capital Management and Boxer Capital - - New investors Janus Henderson Investors, RTW Investments and Invus also participated along with previous Series B investors including MPM Capital and HBM Partners - Cambridge, MA and Gosselies, Belgium – April 1, 2020 – iTeos Therapeutics Inc., a privately-held clinical-stage biotechnology company developing innovative cancer immunotherapies, announced today the closing of an oversubscribed Series B2 financing, which raised a total of $125 million. The Series B2 financing round was co-led by RA Capital Management and Boxer Capital, and included new investors Janus Henderson Investors, RTW Investments and Invus along with existing investors MPM Capital, HBM Partners, 6 Dimensions Capital, Curative Ventures, Fund+, VIVES Louvain Technology Fund, SRIW, and SFPI. Proceeds from the financing will support the Company's continued growth and advance the clinical development of its two lead product candidates, EOS-850, a best-in-class adenosine A2A receptor antagonist and EOS-448, an ADCC-enabled anti-TIGIT antibody. EOS-850 is currently being evaluated in a Phase 1/2 clinical trial both as a single agent and in combination in several solid tumor indications. The Company plans to initiate dosing for the combination cohorts for this trial in the second quarter of 2020. The Company also recently initiated the Phase 1 portion of a Phase 1/2 clinical study of EOS-448, currently being evaluated in patients with solid tumors and hematological malignancies. Proceeds from this financing will also support the advancement of additional first-in-class preclinical programs targeting the adenosine pathway and Tregs. "We are very pleased to have the strong support of this leading class of investors who share our excitement for the highly innovative oncology therapies we have developed at iTeos,” said Michel Detheux, PhD, President and Chief Executive Officer at iTeos. “We look forward to accelerating and expanding our clinical development efforts to identify the most promising indications and combinations for people suffering with cancer. This financing maximizes our ability to execute our development plans alone or in partnership.” "iTeos’ pipeline of best-in-class agents has the potential to usher in a new wave of immuno-oncology therapeutics and the Company is well-positioned to make a significant, positive impact in the treatment of patients with a wide variety of cancer types,” commented Derek DiRocco, Principal, RA Capital Management. “We are thrilled to collaborate with this experienced group of high-quality investors and partner with the iTeos management team as they continue to innovate and progress these exciting programs through clinical development.” “The iTeos team has done a remarkable job developing a pipeline of differentiated, potentially best-in-class cancer therapies,” said Aaron Davis, Co-Founder and Chief Executive Officer, Boxer Capital of the Tavistock Group.  “We are pleased to be joining them as they continue to execute and implement their vision for transforming the cancer treatment landscape.” Derek DiRocco and Aaron Davis will join the iTeos Board as Non-Executive Directors. About iTeos Therapeutics iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to transforming the lives of people living with cancer by designing and developing next generation immunotherapies targeting two key resistance pathways to checkpoint therapy: the adenosine pathway and regulatory T cells (Tregs). The Company’s lead program, EOS-850, is a best-in-class adenosine A2A receptor antagonist currently in a Phase 1/2 study. Its second program, a fully human ADCC-enabling anti-TIGIT antibody (EOS-448), entered the clinic in February 2020. iTeos Therapeutics is headquartered in Cambridge, MA with a world-class research center in Gosselies, Belgium. For more information, please visit www.iteostherapeutics.com. About RA Capital Management RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to provide seed funding to startups and to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with fewer capital concerns from inception through commercialization. For more information, please visit https://www.racap.com. About Boxer Capital, LLC Boxer Capital, LLC is a private biotechnology investment fund based in San Diego, California that invents and invests in drug development across multiple therapeutic indications.  Founded by the life sciences team at Tavistock Group in 2005, Boxer Capital maintains a concentrated portfolio of public and private companies.  For more information, please visit www.boxercap.com.   For further information, please contact: Michel Detheux, CEO iTeos Therapeutics SA info@iteostherapeutics.com   Amber Fennell, Paul Kidwell, Matthew Neal and Sukaina Virji Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com   Sarah McCabe and Zofia Mita Stern Investor Relations, Inc. + 1 212 362 1200 iTeos@sternir.com